Abbott Receives FDA Clearance For Its Imaging Technology Using Artificial Intelligence For Vessels in the Heart

Search jobs
04-Aug-2021
Abbott Receives FDA Clearance For Its Imaging Technology Using Artificial Intelligence For Vessels in the Heart
- Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using Artificial Intelligence
- The new intuitive interface provides step-by-step guidance to enhance ease of use
- When combined with Abbott's Dragonfly OpStar™ imaging catheter and PressureWire X™, the platform provides physicians with a comprehensive set of tools to provide better patient care
Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making and provide the best pathway for treatment.

Related Keywords

New York , United States , Japan , Ziad Ali , Dematteis Cardiovascular Institute At St , Ultreon Software , Linkedin , Facebook , Drug Administration , Heart Center , Artificial Intelligence , Dragonfly Opstar , Dematteis Cardiovascular Institute , Francis Hospital , Beyond Intervention , Nick West , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் , ஜப்பான் , ஜீயத் அலி , சென்டர் , முகநூல் , இதயம் மையம் , செயற்கை உளவுத்துறை , பிரான்சிஸ் மருத்துவமனை , அப்பால் தலையீடு , நிக் மேற்கு ,